Fermenta Biotech Ltd
FERMENTAFermenta Biotech Ltd's price has outrun its earnings. +38.5% in a year against EPS −6.6% — the market is paying now for delivery later.
The sharpest disagreement: the price moved +38.5% in a year while annual EPS moved −6.6% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (4 weeks in) while the P/E sits at the 76th percentile of its own 10-year range. Underneath, the last four quarters read deteriorating — profit −42.4% year on year, and 110% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Fermenta Biotech Ltd trades at ₹501, in a confirmed uptrend and 4 weeks into that stage. That is +47.0% against its own 200-day average. It sits at 100% of a 52-week range of ₹263 to ₹501. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 9 straight weeks.
Today the stock is in a confirmed uptrend — week 4 of stage 2, confirmed. At ₹501 it trades +47.0% versus its 200-day average and sits at 100% of its 52-week range (₹263–₹501).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +730% while the NIFTY 500 moved +276% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 9 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Fermenta Biotech Ltd trades at 23.4× P/E, at the pricey end of its own range (76th percentile). Its long-run median P/E is 15.4×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 23.4× is at the pricey end of its own range (76th percentile), against a long-run median of 15.4× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −6.6% against a +38.5% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the +9.9%/yr price move, ~+6.8%/yr came from earnings growth and ~+3.1 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Fermenta Biotech Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 10 quarters across 2 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +11.8% | +14.4% | +6.8% | +12.9% |
| Profit | −7.9% | — | +10.2% | +42.7% |
| EPS | −6.6% | — | +9.5% | — |
| Share price | +38.5% | +51.6% | +9.9% | +23.9% |
4-Factor Sector Score
56.3/100 — rank 5 of 14 in Pharma - API · 70% evidence confidence
Fermenta Biotech Ltd scores 56.3 out of 100 against the 14 companies it is compared with in Pharma - API, ranking 5. Price leads the evidence: RS versus the benchmark is 49.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
The four contributions add to the total exactly: 11.4 + 18 + 11 + 15.9 = 56.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Fermenta Biotech Ltd reported ₹122 Cr of revenue in the Mar 26 quarter, −12.9% year on year. Over 10 years it has compounded at 12.9% a year. The last full year, FY26, came in at ₹523 Cr. The last four reported quarters add to ₹525 Cr.
FY26 revenue came in at ₹523 Cr (+11.8% on the year), capping 10 years at 12.9% compound. The latest quarter (Mar 26) printed ₹122 Cr, −12.9% year on year.
Pace check: the last four quarters averaged +21.5% growth against the decade's 12.9% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +11.9% over the last 4 quarters against +25.2%/yr over the last 8 — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Fermenta Biotech Ltd's operating margin is 16.0% in the Mar 26 quarter, −10.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 5.0% to 39.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 16.0%, −10.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 5.0%–39.0%.
🚨 Why the margin moved: operating margin went −10.0 pp year on year while gross margin went +3.5 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Fermenta Biotech Ltd earned ₹19.0 Cr of net profit in the Mar 26 quarter, −42.4% year on year. Full-year FY26 profit was ₹70.0 Cr. The 10-year compound rate is 42.7%. That is 15.6% of the quarter's revenue. The same quarter a year earlier earned ₹33.0 Cr. 3 of the last 12 reported quarters were loss-making.
Mar 26 profit was ₹19.0 Cr, −42.4% year on year. On the full year, FY26 printed ₹70.0 Cr (−7.9%), and the 10-year compound rate is 42.7%.
🚨 Why profit moved: revenue contributed −12.9% and the margin −10.0 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit −15.7% vs revenue +21.5%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 110% of Fermenta Biotech Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹93.0 Cr of operating cash against ₹70.0 Cr of profit. After ₹12.0 Cr of capital spending, ₹81.0 Cr was left as free cash.
FY26: operating cash of ₹93.0 Cr against reported profit of ₹70.0 Cr, leaving free cash of ₹81.0 Cr after ₹12.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 110% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 110%: the cash cycle tightened 117 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Fermenta Biotech Ltd's cash conversion cycle runs 221 days in FY26, down from 338 days in FY21. Capital spending ran ₹−8.0 Cr over the last 3 years. At FY26 sales of ₹523 Cr each day of that cycle holds about ₹1.4 Cr, so roughly ₹317 Cr sits inside the business at any moment.
FY26: debtors at 78 days, inventory at 290 days — roughly 9.5 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 221 days, tighter than FY21's 338.
The full loop: cash goes out to suppliers and production on day 0; stock waits 290 days to sell; customers pay about 78 days after that; and suppliers themselves are paid at 147 days — netting out to the 221-day cycle.
In money terms: at FY26 sales of ₹523 Cr, each day of the cycle holds about ₹1.4 Cr — so the 221-day loop keeps roughly ₹317 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹−8.0 Cr over the last 3 fiscal years against ₹71.0 Cr of depreciation — spending at or below maintenance level. Capital work-in-progress stands at ₹13.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Fermenta Biotech Ltd earns a ROCE of 21% in FY26. That is up from a trough of 0% in FY23. Return on invested capital clears the cost of that capital by +0.5 percentage points, so growth here adds value rather than only size. The wiring behind it is 13.4% net margin on 0.81× asset turns.
FY26 ROCE is 21%, recovered from a FY23 trough of 0% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 13.4% net margin × 0.81× asset turns × 1.60× balance-sheet leverage ≈ 17.4% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 12.5% − 12.0% = a +0.5 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Fermenta Biotech Ltd carries total debt of ₹113 Cr against shareholder equity of ₹401 Cr as of Mar 26, a debt-to-equity of 0.28 — effectively unlevered. On the annual view that ratio went from 0.64 in FY22 to 0.28 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹113 Cr against shareholder equity of ₹401 Cr — a debt-to-equity of 0.28. On the annual view, debt-to-equity went from 0.64 (FY22) to 0.28 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters added 2.0 points of Fermenta Biotech Ltd over 8 quarters, the biggest move on the register. That takes promoters to 64.1% of the company. Foreign institutions moved +0.1 points over the same window, to 0.1%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: +2.0 points over 8 quarters to 64.1%; Foreign institutions: +0.1 points over 8 quarters to 0.1%; Domestic institutions: +0.0 points over 8 quarters to 0.0%.
Why the register moved: promoters drove it (+2.0 points) — steady accumulation by institutions reading the same numbers this page reads.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Fermenta Biotech Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Senores Pharmaceuticals LtdSENORES | 73.8/100Favorable setup75% evidence | LEADER | 32.4/35 Revenue 50.9% · PAT 92.7% · OPM change 5 pp 95% evidence | 16.4/25 ROCE 15.1% · OPM 30% 76% evidence | 9.4/20 P/E 47.6× · PEG — 15% evidence | 15.6/20 RS sector 19.5% · RS bench 44.3% · 1Y 95.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 32.4 + 16.4 + 9.4 + 15.6 = 73.8 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Wanbury LtdWANBURY | 71.2/100Favorable setup73% evidence | TURNING | 25.7/35 Revenue 16.5% · PAT 45.5% · OPM change 6 pp 71% evidence | 19.5/25 ROCE 36.6% · OPM 16% 95% evidence | 12.1/20 P/E 23.9× · PEG — 50% evidence | 13.9/20 RS sector 5.3% · RS bench 12.9% · 1Y 20.1%7 of 11 weeks ahead 70% evidence |
| Exact sum: 25.7 + 19.5 + 12.1 + 13.9 = 71.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3Innova Captab LtdINNOVACAP | 65.1/100Favorable setup96% evidence | LEADER | 22.2/35 Revenue 31.1% · PAT 10.2% · OPM change 0 pp 88% evidence | 15.6/25 ROCE 15% · OPM 15% 100% evidence | 13.8/20 P/E 39.7× · PEG 1.01 100% evidence | 13.5/20 RS sector -1.4% · RS bench 19.9% · 1Y 7.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 15.6 + 13.8 + 13.5 = 65.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Jagsonpal Pharmaceuticals LtdJAGSNPHARM | 56.9/100Mixed-positive evidence81% evidence | TURNING | 15.7/35 Revenue 3.2% · PAT -24.6% · OPM change 2 pp 95% evidence | 18.2/25 ROCE 22.7% · OPM 21% 95% evidence | 11.2/20 P/E 32.4× · PEG — 50% evidence | 11.8/20 RS sector 0.7% · RS bench 9.7% · 1Y -12.3%10 of 10 weeks ahead 70% evidence |
| Exact sum: 15.7 + 18.2 + 11.2 + 11.8 = 56.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Fermenta Biotech Ltdthis pageFERMENTA | 56.3/100Mixed-positive evidence70% evidence | TURNING | 11.4/35 Revenue 11.9% · PAT -6.6% · OPM change -10 pp 83% evidence | 18.0/25 ROCE 20.6% · OPM 16% 95% evidence | 11.0/20 P/E 23.4× · PEG — 15% evidence | 15.9/20 RS sector 15.7% · RS bench 49.3% · 1Y 33.5%3 of 7 weeks ahead 70% evidence |
| Exact sum: 11.4 + 18 + 11 + 15.9 = 56.3 · Decision use: Price leads the evidence: RS versus the benchmark is 49.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 6Ind-Swift Laboratories LtdINDSWFTLAB | 55.3/100Mixed-positive evidence83% evidence | BREAKING OUT | 22.3/35 Revenue 100% · PAT -80% · OPM change 19 pp 83% evidence | 6.5/25 ROCE 4.7% · OPM 12% 95% evidence | 6.5/20 P/E 39.4× · PEG — 50% evidence | 20.0/20 RS sector 39.4% · RS bench 68% · 1Y 114.3%9 of 12 weeks ahead 100% evidence |
| Exact sum: 22.3 + 6.5 + 6.5 + 20 = 55.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Aarti Drugs LtdAARTIDRUGS | 49.3/100Mixed-negative evidence94% evidence | TURNING | 18.2/35 Revenue 10.5% · PAT 1.1% · OPM change 1 pp 100% evidence | 10.6/25 ROCE 11.9% · OPM 14% 100% evidence | 13.3/20 P/E 20× · PEG 2.4 100% evidence | 7.2/20 RS sector -10.7% · RS bench 0.7% · 1Y -21.4%4 of 10 weeks ahead 70% evidence |
| Exact sum: 18.2 + 10.6 + 13.3 + 7.2 = 49.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Anuh Pharma LtdANUHPHR | 47.8/100Mixed-negative evidence77% evidence | ASLEEP | 16.6/35 Revenue 16.5% · PAT -12.8% · OPM change 1 pp 83% evidence | 11.1/25 ROCE 14.9% · OPM 10% 95% evidence | 13.1/20 P/E 21.9× · PEG — 50% evidence | 7.0/20 RS sector -5.4% · RS bench -2.9% · 1Y -20%0 of 10 weeks ahead 70% evidence |
| Exact sum: 16.6 + 11.1 + 13.1 + 7 = 47.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Beta Drugs LtdBETA | 45.6/100Mixed-negative evidence76% evidence | TURNING | 11.7/35 Revenue -11.3% · PAT -14.8% · OPM change 2 pp 95% evidence | 18.6/25 ROCE 19.2% · OPM 22% 76% evidence | 7.1/20 P/E 51× · PEG — 50% evidence | 8.2/20 RS sector -17.9% · RS bench 35.1% · 1Y 30.5%9 of 10 weeks ahead 70% evidence |
| Exact sum: 11.7 + 18.6 + 7.1 + 8.2 = 45.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Kopran LtdKOPRAN | 42.1/100Mixed-negative evidence77% evidence | TURNING | 16.6/35 Revenue 8.3% · PAT -34.2% · OPM change 4 pp 83% evidence | 9.6/25 ROCE 6.7% · OPM 14% 95% evidence | 8.1/20 P/E 35.8× · PEG — 50% evidence | 7.8/20 RS sector -17.6% · RS bench 19.4% · 1Y 10.6%11 of 11 weeks ahead 70% evidence |
| Exact sum: 16.6 + 9.6 + 8.1 + 7.8 = 42.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Gujarat Themis Biosyn LtdGUJTHEM | 39.8/100Mixed-negative evidence89% evidence | ASLEEP | 14.8/35 Revenue 8.6% · PAT -6.1% · OPM change 2 pp 88% evidence | 18.3/25 ROCE 17.9% · OPM 44% 100% evidence | 6.4/20 P/E 83.6× · PEG 2.77 65% evidence | 0.3/20 RS sector -22.1% · RS bench -4.7% · 1Y -1.2%10 of 12 weeks ahead 100% evidence |
| Exact sum: 14.8 + 18.3 + 6.4 + 0.3 = 39.8 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 12Themis Medicare LtdTHEMISMED | 28.7/100Adverse evidence68% evidence | BREAKING OUT | 13.0/35 Revenue -15.6% · PAT -80% · OPM change 15.7 pp 62% evidence | 2.4/25 ROCE 2.7% · OPM 4.9% 95% evidence | 8.5/20 P/E 587× · PEG — 15% evidence | 4.8/20 RS sector -17.2% · RS bench 0.9% · 1Y -10%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13 + 2.4 + 8.5 + 4.8 = 28.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Aarti Pharmalabs LtdAARTIPHARM | 27.4/100Adverse evidence90% evidence | ASLEEP | 7.3/35 Revenue -14% · PAT -31.3% · OPM change -7 pp 88% evidence | 11.3/25 ROCE 10.7% · OPM 19% 100% evidence | 3.3/20 P/E 34.2× · PEG 5.52 100% evidence | 5.5/20 RS sector -10.7% · RS bench -11.7% · 1Y -29.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 7.3 + 11.3 + 3.3 + 5.5 = 27.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Orchid Pharma LtdORCHPHARMA | 19.0/100Adverse evidence90% evidence | TURNING | 5.9/35 Revenue -11.8% · PAT -79.8% · OPM change -1 pp 88% evidence | 2.9/25 ROCE 2.6% · OPM 11% 100% evidence | 2.7/20 P/E 184× · PEG 4.09 100% evidence | 7.5/20 RS sector -19.8% · RS bench 29.8% · 1Y 38.9%11 of 11 weeks ahead 70% evidence |
| Exact sum: 5.9 + 2.9 + 2.7 + 7.5 = 19 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Fermenta Biotech Ltd's share price today?
Fermenta Biotech Ltd trades at ₹501, +38.5% over the past year. The company is valued at ₹1,476 Cr. The stock sits at 100% of its 52-week range of ₹263–₹501, +47.0% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 4 weeks in. — as of 31 July 2026.
What were Fermenta Biotech Ltd's latest quarterly results?
Fermenta Biotech Ltd reported revenue of ₹122 Cr and net profit of ₹19.0 Cr for the Mar 26 quarter. Revenue fell 12.9% and profit fell 42.4% year on year. Earnings per share were ₹6.52. The operating margin was 16.0%, 10.0 pp lower than a year earlier. — as of 31 July 2026.
What is Fermenta Biotech Ltd's revenue?
Fermenta Biotech Ltd reported revenue of ₹122 Cr in the Mar 26 quarter, −12.9% year on year. For the full FY26 fiscal year, revenue was ₹523 Cr (+11.8%). Over the last 10 years revenue compounded at 12.9% a year. — as of 31 July 2026.
What is Fermenta Biotech Ltd's profit?
Fermenta Biotech Ltd earned ₹19.0 Cr of net profit in the Mar 26 quarter, −42.4% year on year. Full-year FY26 profit was ₹70.0 Cr. The operating margin ran 16.0% in the latest quarter. — as of 31 July 2026.
What is Fermenta Biotech Ltd's market cap?
Fermenta Biotech Ltd's market capitalisation is ₹1,476 Cr at a share price of ₹501. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Fermenta Biotech Ltd's P/E ratio?
Fermenta Biotech Ltd trades at a P/E of 23.4×, at the 76th percentile of its own 10-year range, against a long-run median of 15.4×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Fermenta Biotech Ltd pay a dividend?
Yes — Fermenta Biotech Ltd's dividend payout was 15% of profit in FY26, and it recorded a payout in 9 of its last 13 reported fiscal years. 4 of those years show a negative ratio because profit itself was negative. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Fermenta Biotech Ltd overvalued?
On its own history, Fermenta Biotech Ltd looks expensive against its own history: its P/E of 23.4× sits at the 76th percentile of its 10-year range (long-run median 15.4×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Fermenta Biotech Ltd growing?
Not right now — Fermenta Biotech Ltd's latest numbers are shrinking: latest-quarter revenue −12.9% year on year, profit −42.4%, and the margin −10.0 pp at 16.0%. The 10-year compound rates are 12.9% (revenue) and 42.7% (profit). The earnings engine currently reads: deteriorating — as of 31 July 2026.
How is Fermenta Biotech Ltd performing?
Fermenta Biotech Ltd is in a confirmed uptrend, 4 weeks in. Its latest quarter's revenue fell 12.9% and profit fell 42.4% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 9 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
Is Fermenta Biotech Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 4 of stage 2), trading +47.0% versus its 200-day average and at 100% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Fermenta Biotech Ltd beating the market?
On recent form, yes — Fermenta Biotech Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 9 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +730% against the NIFTY 500's +276% — ahead of the index over the full window. — as of 31 July 2026.
Will Fermenta Biotech Ltd's share price go up?
This page publishes no price forecast for Fermenta Biotech Ltd. What it measures instead: the share price is ₹501, the price is in a confirmed uptrend 4 weeks in. Its P/E of 23.4× sits at the 76th percentile of its own 10-year range. — as of 31 July 2026.
Who owns Fermenta Biotech Ltd?
Promoters hold 64.1% of Fermenta Biotech Ltd, foreign institutions 0.1%, domestic institutions 0.0% and the public 33.2% (latest quarter). The biggest move on the register over the last two years: Promoters added 2.0 points over 8 quarters. — as of 31 July 2026.
Does Fermenta Biotech Ltd have too much debt?
No — Fermenta Biotech Ltd's debt-to-equity is 0.28, and operating profit covers the interest bill 8×. FY26 borrowings were ₹113 Cr against equity of ₹406 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is Fermenta Biotech Ltd's capex?
Fermenta Biotech Ltd spent ₹−8.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹12.0 Cr, with ₹13.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Fermenta Biotech Ltd's cash flow?
Fermenta Biotech Ltd generated ₹93.0 Cr of operating cash flow in FY26 and ₹81.0 Cr of free cash flow after ₹12.0 Cr of capital spending. Reported profit that year was ₹70.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Fermenta Biotech Ltd's profit real cash?
Yes — over the last 3 fiscal years, 110% of Fermenta Biotech Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹93.0 Cr against reported profit of ₹70.0 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Fermenta Biotech Ltd in its business cycle?
Fermenta Biotech Ltd's FY26 operating margin was 19.0%, against a 13-year band of 5.0%–39.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 16.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Fermenta Biotech Ltd story?
The sharpest disagreement: the price moved +38.5% in a year while annual EPS moved −6.6% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Fermenta Biotech Ltd a stock worth studying right now?
This is not investment advice. The machine read: Fermenta Biotech Ltd's price has outrun its earnings. +38.5% in a year against EPS −6.6% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.